FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016171635> ?p ?o ?g. }

• W2016171635 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCBackground: MEK inhibitors such as BAY86-9766 are a new class of agents that show promise in the treatment of non-small cell lung cancer (NSCLC). The downstream effects of MEK inhibition in NSCLC have not been fully elucidated. We performed a broad proteomic analysis to determine which signaling pathways were modulated by BAY86-9766 treatment and how these pathways correlate with sensitivity.Methods: We treated 109 lung cancer cell lines with MEK inhibitor BAY86-9766 at a concentration of 2200 nM. Drug sensitivity was determined by CellTiter-Glo assay and cell lines were classified as sensitive or resistant based on whether their IC50 values were in the highest or lowest 1/3rd of those tested. Using paired t-tests, we compared pre- versus post-treatment protein levels in the overall group and between the sensitive vs. resistant cell lines.Results: MEK inhibitor BAY86-9766 was effective in reducing phosphorylation of direct downstream signaling molecules pMAPK (p<0.0001) and p-P90RSK (p<0.02). There was no significant difference in the level of pMAPK suppression between sensitive and resistant cell lines (p=0.55). In contrast, LKB1/AMPK activation was observed following MEK inhibitor treatment, as illustrated by higher post-treatment levels of LKB1 total protein, pAMPK, and pTSC2 (all p values <0.02). As a consequence of these changes, the activity of downstream mTOR was suppressed, as evidenced by decreased pS6 (S235/236), pS6 (S240/244) and phospho-p70S6K and increased pPDK1 (all p≤0.002). All of these changes were significantly more pronounced in sensitive cell lines vs resistant cell lines (all p<0.01). We also saw evidence of activation of feedback loops, as Src significantly increased in sensitive cell lines compared to resistant cell lines (p=0.0009).Conclusions: We have performed broad proteomic analysis on cell lines treated with MEK inhibitor BAY86-9766 to determine which pathways are modulated by treatment and how they might relate to sensitivity. We conclude that MEK inhibition with BAY86-9766 may exert some of its effects by suppressing mTOR activity via the LKB1/AMPK pathway, and that the degree of modulation of the AMPK pathway correlates with sensitivity. This mechanism may involve decreased activation of p90RSK by MAPK, which leads to decreased degradation and increased activity of LKB1, and thereby increased AMPK activity and decreased mTOR signaling. This works suggests a rational basis for combinations of targeted agents to overcome resistance, such as combinations of MEK inhibitors with mTOR inhibitors or PI3 kinase inhibitors.Citation Format: Kathryn A. Gold, Lauren A. Byers, You Hong Fan, Lixia Diao, Philip Groth, Julianne Paul, Jing Wang, Uma Giri, Jayanthi Gudikote, Hai T. Tran, Kevin R. Coombes, John D. Minna, Ningshu Liu, John V. Heymach. Proteomic analysis of effects of MEK inhibition with BAY86-9766 on LKB1/AMPK and mTOR pathway in lung cancer cell lines. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1045. doi:10.1158/1538-7445.AM2013-1045" @default.
• W2016171635 created "2016-06-24" @default.
• W2016171635 creator A5028358775 @default.
• W2016171635 creator A5037677450 @default.
• W2016171635 creator A5038912570 @default.
• W2016171635 creator A5048380048 @default.
• W2016171635 creator A5048865240 @default.
• W2016171635 creator A5056267838 @default.
• W2016171635 creator A5059903431 @default.
• W2016171635 creator A5066245619 @default.
• W2016171635 creator A5066837969 @default.
• W2016171635 creator A5067755477 @default.
• W2016171635 creator A5074180677 @default.
• W2016171635 creator A5079259757 @default.
• W2016171635 creator A5080830668 @default.
• W2016171635 creator A5089771018 @default.
• W2016171635 date "2013-04-15" @default.
• W2016171635 modified "2023-09-25" @default.
• W2016171635 title "Abstract 1045: Proteomic analysis of effects of MEK inhibition with BAY86-9766 on LKB1/AMPK and mTOR pathway in lung cancer cell lines." @default.
• W2016171635 doi "https://doi.org/10.1158/1538-7445.am2013-1045" @default.
• W2016171635 hasPublicationYear "2013" @default.
• W2016171635 type Work @default.
• W2016171635 sameAs 2016171635 @default.
• W2016171635 citedByCount "0" @default.
• W2016171635 crossrefType "proceedings-article" @default.
• W2016171635 hasAuthorship W2016171635A5028358775 @default.
• W2016171635 hasAuthorship W2016171635A5037677450 @default.
• W2016171635 hasAuthorship W2016171635A5038912570 @default.
• W2016171635 hasAuthorship W2016171635A5048380048 @default.
• W2016171635 hasAuthorship W2016171635A5048865240 @default.
• W2016171635 hasAuthorship W2016171635A5056267838 @default.
• W2016171635 hasAuthorship W2016171635A5059903431 @default.
• W2016171635 hasAuthorship W2016171635A5066245619 @default.
• W2016171635 hasAuthorship W2016171635A5066837969 @default.
• W2016171635 hasAuthorship W2016171635A5067755477 @default.
• W2016171635 hasAuthorship W2016171635A5074180677 @default.
• W2016171635 hasAuthorship W2016171635A5079259757 @default.
• W2016171635 hasAuthorship W2016171635A5080830668 @default.
• W2016171635 hasAuthorship W2016171635A5089771018 @default.
• W2016171635 hasConcept C104317684 @default.
• W2016171635 hasConcept C11960822 @default.
• W2016171635 hasConcept C121608353 @default.
• W2016171635 hasConcept C126322002 @default.
• W2016171635 hasConcept C127561419 @default.
• W2016171635 hasConcept C185592680 @default.
• W2016171635 hasConcept C2776256026 @default.
• W2016171635 hasConcept C2777752497 @default.
• W2016171635 hasConcept C2780124434 @default.
• W2016171635 hasConcept C2781249067 @default.
• W2016171635 hasConcept C502942594 @default.
• W2016171635 hasConcept C54355233 @default.
• W2016171635 hasConcept C55493867 @default.
• W2016171635 hasConcept C57074206 @default.
• W2016171635 hasConcept C62478195 @default.
• W2016171635 hasConcept C71924100 @default.
• W2016171635 hasConcept C75217442 @default.
• W2016171635 hasConcept C81885089 @default.
• W2016171635 hasConcept C86554907 @default.
• W2016171635 hasConcept C86803240 @default.
• W2016171635 hasConcept C95444343 @default.
• W2016171635 hasConcept C97029542 @default.
• W2016171635 hasConcept C98274493 @default.
• W2016171635 hasConceptScore W2016171635C104317684 @default.
• W2016171635 hasConceptScore W2016171635C11960822 @default.
• W2016171635 hasConceptScore W2016171635C121608353 @default.
• W2016171635 hasConceptScore W2016171635C126322002 @default.
• W2016171635 hasConceptScore W2016171635C127561419 @default.
• W2016171635 hasConceptScore W2016171635C185592680 @default.
• W2016171635 hasConceptScore W2016171635C2776256026 @default.
• W2016171635 hasConceptScore W2016171635C2777752497 @default.
• W2016171635 hasConceptScore W2016171635C2780124434 @default.
• W2016171635 hasConceptScore W2016171635C2781249067 @default.
• W2016171635 hasConceptScore W2016171635C502942594 @default.
• W2016171635 hasConceptScore W2016171635C54355233 @default.
• W2016171635 hasConceptScore W2016171635C55493867 @default.
• W2016171635 hasConceptScore W2016171635C57074206 @default.
• W2016171635 hasConceptScore W2016171635C62478195 @default.
• W2016171635 hasConceptScore W2016171635C71924100 @default.
• W2016171635 hasConceptScore W2016171635C75217442 @default.
• W2016171635 hasConceptScore W2016171635C81885089 @default.
• W2016171635 hasConceptScore W2016171635C86554907 @default.
• W2016171635 hasConceptScore W2016171635C86803240 @default.
• W2016171635 hasConceptScore W2016171635C95444343 @default.
• W2016171635 hasConceptScore W2016171635C97029542 @default.
• W2016171635 hasConceptScore W2016171635C98274493 @default.
• W2016171635 hasLocation W20161716351 @default.
• W2016171635 hasOpenAccess W2016171635 @default.
• W2016171635 hasPrimaryLocation W20161716351 @default.
• W2016171635 hasRelatedWork W1569244960 @default.
• W2016171635 hasRelatedWork W1601811132 @default.
• W2016171635 hasRelatedWork W1860343172 @default.
• W2016171635 hasRelatedWork W1924499370 @default.
• W2016171635 hasRelatedWork W1973870621 @default.
• W2016171635 hasRelatedWork W1997180526 @default.
• W2016171635 hasRelatedWork W2026629856 @default.
• W2016171635 hasRelatedWork W2046635534 @default.
• W2016171635 hasRelatedWork W2068121136 @default.
• W2016171635 hasRelatedWork W2071867468 @default.
• W2016171635 hasRelatedWork W2088302799 @default.
• W2016171635 hasRelatedWork W2099516828 @default.

• next